Angiogenesis Antibody Panel Reference: ARG30328 Angiogenesis antibody; Collagen IV antibody; CD34 antibody; NG2 / Chondroitin sulfate proteoglycan 4 antibody; alpha smooth muscle Actin antibody
Miptenalimab Reference: HY-P99736 Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (KD: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II.
Pyroptosis Antibody Panel Reference: ARG30330 Pyroptosis antibody; GSDMD antibody; Caspase 1 antibody; beta Tubulin antibody; IL1 beta antibody
Ranibizumab (anti-VEGF) Reference: HY-P9951A Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165). Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research.
NLRP3 Inflammasome Antibody Panel Reference: ARG30331 NLRP3 Inflammasome antibody; GAPDH antibody; NALP3 / Cryopyrin antibody; Caspase 1 antibody; ASC / TMS1 antibody
Anifrolumab Reference: HY-P99168 Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research.
NLRC4 Inflammasome Antibody Panel Reference: ARG30332 NLRC4 Inflammasome antibody; GAPDH antibody; Caspase 1 antibody; NLRC4 / CARD12 antibody; ASC / TMS1 antibody
Cemiplimab Reference: HY-P99203 Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research.
M1/M2/TAM Marker Antibody Panel Reference: ARG30333 M1/M2/TAM Marker antibody; CD68 antibody; CD206 / MMR antibody; iNOS antibody; CD163 antibody
Aducanumab Reference: HY-P9967 Aducanumab (BIIB037), a human monoclonal antibody selective for aggregated forms of amyloid beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research.
Tumor-infiltrating Lymphocyte Antibody Panel Reference: ARG30334 Tumor-infiltrating Lymphocyte antibody; CD3 antibody; CD4 antibody; CD20 antibody; CD8 antibody
Bamlanivimab Reference: HY-P99344 Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab.